Teva will record the revenues resulting from sales of the product and remit payments to Anchen and a negotiated percentage of its gross profit to IMPAX. The consumer electronics group Alba added 9p to 577. 5p on whispers that tomorrow’s annual meeting will be accompanied with an upbeat generic wellbutrin trading statement. According to NDCHealth, U. Wellbutrin also is sold as a stop-smoking treatment under the name Zyban. GlaxoSmithKline markets Wellbutrin SR for the treatment generic wellbutrin of depression. In order to assess the potential risks of a generic formulation of bupropion extended-release tablets, Biovail believes it is critical that the FDA require that any Abbreviated New Drug Application (ANDA) for a generic generic wellbutrin version of Wellbutrin XL(R) satisfy the following criteria: a. Under the Company’s previously announced Exclusivity Transfer Agreement with Impax and a subsidiary of Teva, Andrx is entitled to a share of the profits derived from Teva’s sale of this product for a 180-day period. Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Zyban(R) and are indicated as an aid to smoking cessation treatment. These two generic wellbutrin formulation patents expire in 2018. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause IMPAX’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. The companies are embroiled in a lawsuit over whether Eon’s drug, called Bupropion HCI, ER, infringes on Glaxo’s patent for Wellbutrin. For more information about Biovail, visit the company’s Web site at www. Such risks and uncertainties include, but are not limited to, IMPAX’s ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX’s ability to successfully develop and commercialize pharmaceutical products, IMPAX’s reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX’s filings with the Securities and Exchange Commission. With headquarters in Iceland, generic wellbutrin actavis has operations in 40 countries, with 11,000 employees. Generic drugmaker Impax filed an generic wellbutrin abbreviated New Drug Application for a generic version of Wellbutrin SF 200 mg tablets, which has been accepted. Generic wellbutrin wellbutrin XL(R) is indicated for the treatment of major depressive disorder in patients aged 18 and older. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to the Company’s dependence on a relatively small number of products; licensing revenues; the timing and outcome of patent, antitrust and other litigation; the timing and commercial success of future generic product launches; whether the Company will be awarded any market exclusivity period and, if so, the precise dates thereof; government regulation generally; competition; manufacturing capacities, output and quality processes; the Company’s ability to develop and successfully commercialize new products; the loss of revenues from existing products; development and marketing expenses that may not result in commercially successful products; the Company’s inability to obtain, or the high cost of obtaining, licenses for third party technologies; commercial obstacles to the successful introduction of brand products generally, including Fortamet and Cardura XL; the success of the Company’s joint ventures; the impact of returns, allowances and chargebacks; product liability claims; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. The agreement provides, among other things, that if Andrx is unable to launch its own products within generic wellbutrin a defined period of time, and Impax is able to market its products, Andrx will enable Impax to launch its own products. This release and additional information about Andrx Corporation are also available on the Internet at: http://www. Watson Pharmaceuticals initiated shipments of bupropion hydrochloride sustained-release tablets 100 mg under a supply agreement with GlaxoSmithKline last month, following the introduction of a generic Wellbutrin SR to the market by Eon Labs on Jan.